PlaqueTec is pioneering the development of biomarker-based, cardiovascular personalised medicine strategies, using its novel Liquid Biopsy System, to transform the prevention, diagnosis and treatment of Coronary Artery Disease - the leading cause of death worldwide.
Location: United Kingdom
Total raised: $8M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.05.2024 | - | $8M | - |
Mentions in press and media 3
| Date | Title | Description |
| 01.05.2024 | PlaqueTec Raises £6.4M in Funding | PlaqueTec, a Cambridge, UK-based company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), raised £6.4M in funding. The round was led by Lord Moynihan of Chelsea alongside the Future F... |
| 30.04.2024 | PlaqueTec closes $8 million equity financing | The financing was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors Funding will support ongoing BIOPATTERN trial and build BIOCARTA database to transform the treatment of CAD Cambridge, UK, 30 ... |
| - | PlaqueTec | “PlaqueTec is pioneering the development of biomarker-based, cardiovascular personalised medicine strategies, using its novel Liquid Biopsy System, to transform the prevention, diagnosis and treatment of Coronary Artery Disease - the leadin... |